Key facts
- This page summarizes Jack Nielsen's Form 4 filing for Aligos Therapeutics, Inc. (ALGS).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 28 Feb 2024, 17:30.
Jack Nielsen - 27 Feb 2024 Form 4 Insider Report for Aligos Therapeutics, Inc. (ALGS)
- Reporting relationship
- Director
- Issuer ticker
- ALGS
- Reported as of
- 27 Feb 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 28 Feb 2024, 17:30:38 UTC
- Prior SEC filing
- 21 Jul 2023
- Next SEC filing
- 31 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lesley Ann Calhoun, as attorney-in fact for Jack B. Nielsen
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jack Nielsen filed Form 4 for Aligos Therapeutics, Inc. (ALGS) on 28 Feb 2024.
Change
- Previous filing in this sequence was filed on 21 Jul 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ALGS
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -15,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 27 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $26.58
- Footnotes
- F1
ALGS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +4,411
- Change %
- Price
- $0.000000
- Shares after
- 4,411
- Date
- 28 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,411
- Exercise price
- $0.9600
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share.
Footnote F2
The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary.